Stabilized oral psilocin
A pharmaceutical formulation strategy designed to address psilocin's inherent instability.
Partner with usIsraeli preclinical biotech · ALS first
Advancing a new multimodal therapy for ALS.
Haim Pharma is developing stabilized, low-dose oral psilocin for repeated sub-perceptual dosing - a chronic neuropharmacology approach designed for patient-relevant use.
StagePreclinical
First indicationALS
Next objectivePhase I trial readiness
The unmet need
ALS remains devastating, fatal and underserved.
Current treatments offer limited benefit, while most people with ALS still lack a broadly applicable therapy that stops or reverses disease.
≈3 yearsAverage survival after diagnosis
2-3 monthsMedian survival gain with standard therapy
≈2%ALS population addressed by current precision therapy
0Proven therapies that stop or reverse ALS
Our approach
A chronic oral strategy, built around real patient needs.
We are developing an investigational product that brings together a differentiated dosing strategy, pharmaceutical stabilization and an ALS-focused translational program.
Repeated sub-perceptual dosing
A chronic-use development approach distinct from high-dose, session-based psychedelic therapy.
Biomarker-driven development
A translational plan connecting safety, exposure and ALS-relevant biological signals.
Our program is investigational. ALS-specific efficacy, optimal chronic dosing and durability remain to be demonstrated.
The development program
Psilocin, developed for chronic neuropharmacology.
Psilocin is the active compound responsible for psilocybin's pharmacological effects. Haim Pharma's program is designed around low-dose, repeated administration - not psychedelic-assisted psychotherapy.
Our differentiationLow-dose intent · Stabilized formulation · Repeated administration · ALS first
ALS-relevant research rationale
Independent datasets support biological plausibility across several interconnected pathways. Our development plan is designed to test that rationale directly.
Serotonergic signaling
Exploring ALS-relevant signaling and plasticity pathways with human translational measures.
Neuroimmune dysfunction
Testing whether low-dose exposure influences inflammatory biomarkers relevant to ALS biology.
Glutamate excitotoxicity
Investigating effects on cortical excitability and glutamate-linked dysfunction in ALS models.
Team & advisors
Experienced leadership across preclinical, clinical and CMC development.
A lean virtual biotech model with internal control of strategy, IP, regulatory direction, CMC oversight and partner execution.
25+ years' experience
Miriam O'Reilly
Founder & CEO
Biotech development · R&D leadership
20+ years' experience
Rinat Eilat
VP, Preclinical & Strategic Operations
Preclinical strategy · CRO execution
20+ years' experience
Ilanit Blumin Kramer
Director of Operations
Operations · Program coordination
30+ years' experience
Yanir H. Aldouby
CMC & Manufacturing Advisor
CMC · Pharmaceutical manufacturingAdvisors
Specialist ALS and clinical development guidance.
25+ years' experience
Dr. Richard Bedlack
ALS Medical Advisor
Director, Duke ALS Clinic
35+ years' experience
Mary Guilfoyle
Clinical Development Advisor
Established specialist collaborations
Preclinical researchClinical researchDigital biomarkers
Haim Pharma GroupHod HaSharon · Israel
Partner with us
Help advance a new therapeutic strategy for ALS.
We welcome conversations with investors, researchers and development partners who share our urgency for better ALS treatments.
Request our current overviewmiriamoreilly@haimpharmagroup.com